Wed, Apr. 22, 7:17 AM
Tue, Apr. 21, 5:30 PM
Mon, Apr. 20, 1:07 PM
- St. Jude Medical (STJ +0.8%) exercises its option to acquire Menlo Park, CA-based Spinal Modulation for $175M plus additional payments based on FDA clearance of the Axium Neurostimulator System and the achievement of certain revenue targets.
- The company has had a relationship with Spinal Modulation since January 2013, when it secured exclusive rights to distribute Axium in ex-U.S. territories. It also made a $40M equity investment in the intraspinal neuromodulation therapy firm.
- St. Jude expects to complete the transaction this quarter.
Tue, Feb. 24, 9:43 AM
- The FDA grants 510(k) clearance to privately-held Bioness' StimRouter, an implantable neuromodulation device for the treatment of chronic pain of peripheral nerve origin. It is the first implanted device with a specific indication for peripheral nerve stimulation.
- The system consists of an implanted lead , an external pulse transmitter and conductive electrode and a small hand-held wireless control unit.
- Bioness is yet another medical products firm started by serial entrepreneur Al Mann, the force behind Second Sight Medical Products (EYES +21.3%), MannKind (MNKD -1%), Advanced Bionics and MiniMed.
- Neuromodulation-related tickers: (MDT -0.3%)(STJ -1.9%)(BSX)(NURO)
Fri, Feb. 20, 2:48 PM
Wed, Jan. 28, 7:57 AM
- St. Jude Medical (NYSE:STJ) Q4 results ($M): Revenues: 1,439 (+1.2%), International: 761 (-2.6%), U.S.: 678 (+5.8%); ICD: 426 (-3.6%); Pacemakers: 259 (-1.5%); AF: 283 (+12.3%); Cardiovascular: 347 (-0.9%); Neuromodulation: 124 (+7.8%).
- COGS: 425 (-1.2%); R&D Expense: 175 (-5.9%); SG&A Expense: 457 (-3.8%); Net Income: 245 (+99.2%); EPS: 0.84 (+100.0%); Quick Assets: 1,442 (+5.0%).
- Gross Profit: 1,014 (+2.2%); COGS: 29.5% (-2.3%); Gross Margin: 70.5% (+1.0%); Operating Earnings: 382 (+15.4%); Operating Earnings Yield: 26.5% (+14.0%); Net Earnings Yield: 17.0% (+96.8%).
- 2015 Guidance: EPS: $3.50 - 3.55; Non-GAAP EPS: $3.95 - 4.00; Revenues: $5.45B - 5.55B.
- Q1 Guidance: EPS: $0.77 - 0.70; Non-GAAP EPS: $0.90 - 0.92; Revenues: $1.305B - 1.320B.
Wed, Jan. 28, 7:17 AM
Tue, Jan. 27, 5:32 PM
Tue, Jan. 27, 5:30 PM| Tue, Jan. 27, 5:30 PM | 1 Comment
Wed, Jan. 14, 9:56 AM
- St. Jude Medical (STJ +1.1%) announces preliminary revenues for Q4 and its authorization of a $500M share repurchase program.
- Q4: Net sales: ~$1.439B; CRM: $685M, ICD: $426M, Pacemakers: $259M; Atrial fibrillation: $283M; Cardiovascular: $347M, Structural Heart: $159M, Vascular: $188M; Neuromodulation: $124M.
- The company will report final results on January 28 before the open.
Tue, Jan. 6, 8:13 PM
Dec. 11, 2014, 8:21 AM
- St. Jude Medical's (NYSE:STJ) Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P) is now CE Mark-approved in Europe. The Quadra Allure MP is the only quadripolar CRT-P with the MultiPoint Pacing option, which has been shown to enhance patients' responses to CRT.
- The product is designed to work with the Quartet LV lead which has four electrodes, enabling more flexibility in pacing configurations.
Nov. 24, 2014, 3:43 PM
- Twenty-two spinoffs have been completed in 2014, the most in a decade, and another 28 have been announced. Among the catalysts are activist investors, so Credit Suisse screened for companies with multiple business segments, slow growth, and stocks trading for lower multiples than peers, in other words, "good, quality companies that are struggling to grow."
- The list is heavy on big media names like Time Warner (NYSE:TWX) and Twenty-First Century Fox (NASDAQ:FOXA), big tech like Oracle (NYSE:ORCL), Symantec (NASDAQ:SYMC), and IBM, and big industry like Lockheed Martin (NYSE:LMT), Ingersoll-Rand (NYSE:IR), and Raytheon (NYSE:RTN), but just two financial names - Travelers (NYSE:TRV) and Torchmark (NYSE:TMK).
- The rest: MO, CA, WU, DPS, PBI, SJM, HRS, SWK, EMR, WLP, MAT, GE, SNA, LLL, ITW, STJ, PDCO, HPQ, DLPH, HAS, NAVI, GME, CBS, JNJ, SLB.
Nov. 19, 2014, 7:48 AM
- During the scientific sessions at the American Heart Association meeting in Chicago, investigators presented a retrospective data analysis from the CHAMPION clinical trial evaluating the safety and efficacy of St. Jude Medical's (NYSE:STJ) CardioMEMS HF System in patients with New York Heart Association Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months.
- The device is implanted in the pulmonary artery (PA) during a minimally invasive procedure to directly measure PA pressure via a miniaturized wireless monitoring sensor. Measuring PA pressure allows clinicians to proactively manage treatment with medication changes for patients with worsening HF before visible symptoms occur. The system allows patients to transmit PA pressure data from their homes to their doctors enabling them to adjust the meds to reduce the likelihood of hospitalization.
- In patients aged 65 and older, patients implanted with the CardioMEMS HF Systems had 58% fewer all-cause hospital readmissions and 78% fewer HF readmissions compared to standard-of-care medical management. The results suggest that the use of the CardioMEMS HF Systems could reduce a hospital's risk of government-imposed financial penalties from patient readmissions with 30 days of treatment.
Nov. 10, 2014, 10:49 AM
- The Japanese Ministry of Health, Labour and Welfare approves Medtronic's (MDT +0.1%) Evera SureScan implantable cardioverter-defibrillator (ICD) for magnetic resonance imaging (MRI) scans positioned on any region of the body. The commercial launch is underway.
- Evera MRI is available in both single chamber and dual chamber ICDs.
- Until the availability of MR-Conditional ICDs, patients with the devices had been contraindicated from receiving MRI scans because of the potential interactions between the MRI and device function.
- Evera MRI is not yet approved in the U.S.
- Related tickers: (STJ +0.7%)(BSX +1.6%)
Oct. 27, 2014, 11:41 AM
- The FDA approves St. Jude Medical's (STJ -0.3%) TactiCath Quartz irrigated ablation catheter. The product gives physicians a real-time objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure. The technology is associated with a reduction in the rate of atrial fibrillation recurrence when optimal treatment measures are used.
- Related tickers: (BCR +1.2%)(MDT -0.1%)(JNJ +0.9%)(BSX +0.8%)(HNSN +2.1%)(ABT -0.6%)
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.
Other News & PR